SQZ Biotechnologies Company

OTCPK:SQZB Voorraadrapport

Marktkapitalisatie: US$678.3k

SQZ Biotechnologies Beheer

Beheer criteriumcontroles 2/4

SQZ Biotechnologies' CEO is Howard Bernstein, appointed in Nov 2022, has a tenure of 2.08 years. directly owns 0.2% of the company’s shares, worth $1.37K. The average tenure of the management team and the board of directors is 2.9 years and 4.1 years respectively.

Belangrijke informatie

Howard Bernstein

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO2yrs
Eigendom CEO0.2%
Management gemiddelde ambtstermijn2.9yrs
Gemiddelde ambtstermijn bestuur4.1yrs

Recente managementupdates

Recent updates

SQZ Biotechnologies Company (NYSE:SQZ) Might Not Be As Mispriced As It Looks After Plunging 30%

Jun 26
SQZ Biotechnologies Company (NYSE:SQZ) Might Not Be As Mispriced As It Looks After Plunging 30%

We Think SQZ Biotechnologies (NYSE:SQZ) Needs To Drive Business Growth Carefully

Jan 05
We Think SQZ Biotechnologies (NYSE:SQZ) Needs To Drive Business Growth Carefully

SQZ Biotechnologies GAAP EPS of -$0.77 beats by $0.06, revenue of $3.5M misses by $0.76M

Nov 09

SQZ Biotech spikes as H.C. Wainwright initiates with Buy citing platform technology

Oct 20

Is SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Deliver On Growth Plans?

Aug 20
Is SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Deliver On Growth Plans?

SQZ Biotechnologies GAAP EPS of -$0.78 misses by $0.01, revenue of $3.22M misses by $0.97M

Aug 04

SQZ Biotechnologies names business chief as CFO

Jul 11

Time To Worry? Analysts Just Downgraded Their SQZ Biotechnologies Company (NYSE:SQZ) Outlook

May 17
Time To Worry? Analysts Just Downgraded Their SQZ Biotechnologies Company (NYSE:SQZ) Outlook

Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

May 02
Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

Jan 11
Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

Will SQZ Biotechnologies (NYSE:SQZ) Spend Its Cash Wisely?

Jul 30
Will SQZ Biotechnologies (NYSE:SQZ) Spend Its Cash Wisely?

Need To Know: Analysts Are Much More Bullish On SQZ Biotechnologies Company (NYSE:SQZ)

May 16
Need To Know: Analysts Are Much More Bullish On SQZ Biotechnologies Company (NYSE:SQZ)

Newsflash: SQZ Biotechnologies Company (NYSE:SQZ) Analysts Have Been Trimming Their Revenue Forecasts

Mar 25
Newsflash: SQZ Biotechnologies Company (NYSE:SQZ) Analysts Have Been Trimming Their Revenue Forecasts

SQZ Biotechnologies Company (NYSE:SQZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 20
SQZ Biotechnologies Company (NYSE:SQZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

We Think SQZ Biotechnologies (NYSE:SQZ) Can Afford To Drive Business Growth

Feb 01
We Think SQZ Biotechnologies (NYSE:SQZ) Can Afford To Drive Business Growth

Analyse CEO-vergoeding

Hoe is Howard Bernstein's beloning veranderd ten opzichte van SQZ Biotechnologies's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2023n/an/a

-US$72m

Jun 30 2023n/an/a

-US$71m

Mar 31 2023n/an/a

-US$76m

Dec 31 2022US$2mUS$400k

-US$79m

Sep 30 2022n/an/a

-US$78m

Jun 30 2022n/an/a

-US$78m

Mar 31 2022n/an/a

-US$74m

Dec 31 2021US$1mUS$391k

-US$69m

Sep 30 2021n/an/a

-US$75m

Jun 30 2021n/an/a

-US$64m

Mar 31 2021n/an/a

-US$55m

Dec 31 2020US$750kUS$357k

-US$51m

Compensatie versus markt: Insufficient data to establish whether Howard's total compensation is reasonable compared to companies of similar size in the US market.

Compensatie versus inkomsten: Howard's compensation has increased whilst the company is unprofitable.


CEO

Howard Bernstein (67 yo)

2yrs

Tenure

US$1,624,513

Compensatie

Dr. Howard Bernstein, M.D., Ph D., had been Chief Scientific Officer of SQZ Biotechnologies Company since June 2015 until October 31, 2022. Dr. Bernstein is Director of SQZ Biotechnologies Company since Oc...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Howard Bernstein
Interim CEO & Director2yrsUS$1.62m0.20%
$ 1.4k
Lawrence Knopf
General Counsel & Secretary5.2yrsUS$944.03k0.0066%
$ 44.6
Marshelle Warren
Chief Medical Officer2.4yrsUS$944.27k0%
$ 0
Robert Langer
Co-Founder & Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Richard Capasso
Chief Accounting Officer3yrsgeen gegevensgeen gegevens
David First
Chief People Officer4.5yrsgeen gegevensgeen gegevens
Ipsita Roymoulik
Senior Vice President of CMC & QUALITY2.8yrsgeen gegevensgeen gegevens

2.9yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: SQZB's management team is considered experienced (2.9 years average tenure).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Howard Bernstein
Interim CEO & Director2.1yrsUS$1.62m0.20%
$ 1.4k
Robert Langer
Co-Founder & Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
David Sachs
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Amy W. Schulman
Directorno dataUS$104.40k0.74%
$ 5.0k
Patrick V. J. Vink
Independent Director3.3yrsUS$96.62k0%
$ 0
Klavs Jensen
Independent Director11.7yrsUS$89.40k1.15%
$ 7.8k
Bernard Coulie
Independent Chairman3.3yrsUS$94.40k0%
$ 0
Marc Elia
Independent Director6.5yrsUS$86.90k0%
$ 0
Darrell Irvine
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Pushkal Garg
Independent Director6.3yrsUS$94.40k0%
$ 0
Marc Schegerin
Independent Director4.1yrsUS$94.40k0%
$ 0
Arlene Sharpe
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens

4.1yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: SQZB's board of directors are considered experienced (4.1 years average tenure).